Matthew Boron
AstraZeneca (United States) · 11 works · 519 citations · h-index 4
Top works
- Phase II Multicenter Trial of Bevacizumab Plus Fluorouracil and Leucovorin in Patients With Advanced Refractory Colorectal Cancer: An NCI Treatment Referral Center Trial TRC-0301
- Glucarpidase, Leucovorin, and Thymidine for High-Dose Methotrexate-Induced Renal Dysfunction: Clinical and Pharmacologic Factors Affecting Outcome
- Treatment of Accidental Intrathecal Methotrexate Overdose With Intrathecal Carboxypeptidase G2
- Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group
- Carboxypeptidase-G2 (CPDG2) and leucovorin (LV) rescue with and without addition of thymidine (Thd) for high-dose methotrexate (HDMTX) induced renal dysfunction
- Expanded access trial of tocilizumab in COVID19+hospitalized cancer patients
- NCI’s national treatment trial networks: Experience and adaptations during COVID-19.
- Early Access to Investigational Agents through the National Cancer Institute's Treatment Referral Center.
- Abstract PO-092: Expanded access trial of tocilizumab in COVID19+ hospitalized cancer patients
- Perspective: The COVID-19 Pandemic: Closing Borders, Opening Doors, and Breaking Ground on the Potential for Clinical Trial Access in Developing Countries Like Trinidad and Tobago
- P3.01.19 Gender Differences in Lung Cancer Diagnosis, Treatment Patterns and Outcomes: A Systematic Literature Review